Relapsed Refractory Multiple Myeloma (RRMM)Symptoms, Doctors, Treatments, Advances & More
Learn About Relapsed Refractory Multiple Myeloma (RRMM)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
CUIMC/Herbert Irving Pavilion
Suzanne Lentzsch is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Lentzsch is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. Lentzsch is currently accepting new patients.
David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center
Hamza Hashmi is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Hashmi is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hashmi is currently accepting new patients.
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
Paul Richardson is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is board certified in Medical Oncology. Dr. Richardson is currently accepting new patients.
Summary: This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Summary: This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.